CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.
Lee
Anna M
AM
The Centre for Addiction and Mental Health and the Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada M5S 1A8.
Jepson
Christopher
C
Shields
Peter G
PG
Benowitz
Neal
N
Lerman
Caryn
C
Tyndale
Rachel F
RF
D000279:Administration, Cutaneous; D000280:Administration, Inhalation; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D003367:Cotinine / Q000031:analogs & derivatives / Q000097:blood; D065702:Cytochrome P-450 CYP2B6; D005838:Genotype; D006801:Humans; D015810:Linkage Disequilibrium; D009538:Nicotine / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism*; D018722:Nicotinic Agonists / Q000097:blood* / Q000378:metabolism*; D010089:Oxidoreductases, N-Demethylating / Q000235:genetics*; D016540:Smoking Cessation / Q000379:methods
D018722:Nicotinic Agonists; C001381:hydroxycotinine; D009538:Nicotine; D001189:Aryl Hydrocarbon Hydroxylases; C585599:CYP2B6 protein, human; D065702:Cytochrome P-450 CYP2B6; D010089:Oxidoreductases, N-Demethylating; D003367:Cotinine